Bausch & Lomb SofLens (polymacon) Contact Lenses
Bausch + Lomb, Inc. · Decision date Oct 24, 2025
What did the FDA decide?
FDA records N16895/S107 as a supplement to PMA null, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 24, 2025.
FDA approval order statement
use of a New Technology Moulding Machine in the Reverse Process III (RPIII) manufacturing process utilized in the Bausch + Lomb Waterford, Ireland manufacturing facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 24, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- N16895/S107
- Regulatory pathway
- PMA supplement
- Applicant
- Bausch + Lomb, Inc.
- Product code
- LPM
- Decision code
- OK30
- Decision date
- Oct 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- LPM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N16895/S107 received
Application receipt date recorded by FDA.
N16895/S107 · FDA decision
30-Day Notice
Related devices and submissions
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1400 N. Goodman St., Rochester, NY, 14609
Sources and methodology
- Original FDA record: N16895/S107
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

